Li Xiao-Fen, Tan Yi-Nuo, Cao Ying, Xu Jing-Hong, Zheng Shu, Yuan Ying
From the Department of Medical Oncology (X-FL, Y-NT, YC, YY); Department of Pathology (J-HX); and Key Laboratory of Cancer Prevention and Intervention of Ministry of Education, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China (SZ, YY).
Medicine (Baltimore). 2015 Sep;94(39):e1661. doi: 10.1097/MD.0000000000001661.
Apatinib is a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor-2, which shows good efficacy and safety in clinical trials for chemotherapy-refractory gastric cancer patients. Till now, there is no case report after apatinib came in the market. We presented a 55-year-old Chinese woman with advanced gastric cancer, who received apatinib after failure of second-line chemotherapy. On the 19th day of apatinib administration, she suffered from gastrointestinal hemorrhage. Then, her condition rapidly deteriorated to gastrointestinal perforation. Although the patient received timely medical and surgical treatment, she finally died of septic shock. Although apatinib shows exciting efficacy and good tolerance in phase II and III clinical trials, this novel targeted drug should be prescribed carefully and close clinical monitoring is needed when using it.
阿帕替尼是一种新型的靶向血管内皮生长因子受体-2的酪氨酸激酶抑制剂，在化疗难治性胃癌患者的临床试验中显示出良好的疗效和安全性。到目前为止，阿帕替尼上市后尚无病例报告。我们报告了一名55岁的中国晚期胃癌女性患者，在二线化疗失败后接受了阿帕替尼治疗。在服用阿帕替尼的第19天，她出现了胃肠道出血。随后，她的病情迅速恶化为胃肠道穿孔。尽管患者接受了及时的药物和手术治疗，但最终仍死于感染性休克。尽管阿帕替尼在II期和III期临床试验中显示出令人兴奋的疗效和良好的耐受性，但这种新型靶向药物在使用时应谨慎处方，并需要密切的临床监测。
